- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06172296
- Original rettssak
Dinutuximab med kjemoterapi, kirurgi og stamcelletransplantasjon for behandling av barn med nylig diagnostisert høyrisikoneuroblastom
En fase 3-studie av dinutuximab lagt til intensiv multimodal terapi for barn med nylig diagnostisert høyrisikoneuroblastom
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Studieoversikt
Status
Intervensjon / Behandling
- Legemiddel: Carboplatin
- Legemiddel: Cyclophosphamide
- Legemiddel: Cisplatin
- Fremgangsmåte: Bone Marrow Biopsy
- Legemiddel: Doxorubicin
- Legemiddel: Vincristine
- Fremgangsmåte: Magnetic Resonance Imaging
- Fremgangsmåte: Echocardiography Test
- Fremgangsmåte: Multigated Acquisition Scan
- Fremgangsmåte: Bone Marrow Aspiration
- Legemiddel: Etoposide
- Fremgangsmåte: Computed Tomography
- Legemiddel: Topotecan
- Stråling: Radiation Therapy
- Fremgangsmåte: Biospecimen Collection
- Annen: Survey Administration
- Legemiddel: Melphalan
- Legemiddel: Irinotecan
- Legemiddel: Thiotepa
- Biologisk: Dinutuximab
- Fremgangsmåte: FDG-Positron Emission Tomography and Computed Tomography Scan
- Fremgangsmåte: Hematopoietic Cell Transplantation
- Legemiddel: Isotretinoin
- Fremgangsmåte: Leukapheresis
- Fremgangsmåte: Radionuclide Imaging
- Legemiddel: Temozolomide
- Fremgangsmåte: Tumor Resection
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Rekruttering
- Sydney Children's Hospital
-
Hovedetterforsker:
- Draga Barbaric
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: (02) 9382-1721
-
Westmead, New South Wales, Australia, 2145
- Rekruttering
- The Children's Hospital at Westmead
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 61-2-9845 1400
-
Hovedetterforsker:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Rekruttering
- Queensland Children's Hospital
-
Hovedetterforsker:
- Steven A. Foresto
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Rekruttering
- Royal Children's Hospital
-
Hovedetterforsker:
- Martin A. Campbell
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 61 3 9345 5656
- E-post: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Rekruttering
- Perth Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- E-post: helpdesk@childrensoncologygroup.org
-
Hovedetterforsker:
- Michelle Ng
-
-
-
-
-
Québec, Canada, G1V 4G2
- Rekruttering
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Hovedetterforsker:
- Bruno Michon
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-post: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Rekruttering
- Alberta Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-post: research4kids@ucalgary.ca
-
Hovedetterforsker:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- University of Alberta Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-post: pedsoncologyresearch@ahs.ca
-
Hovedetterforsker:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Rekruttering
- British Columbia Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 6477 604-875-2345
-
Hovedetterforsker:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Rekruttering
- CancerCare Manitoba
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-post: ctu_web@cancercare.mb.ca
-
Hovedetterforsker:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Rekruttering
- Janeway Child Health Centre
-
Hovedetterforsker:
- Lisa A. Goodyear
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 709-777-8727
- E-post: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Rekruttering
- IWK Health Centre
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-post: Research@iwk.nshealth.ca
-
Hovedetterforsker:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Rekruttering
- McMaster Children's Hospital at Hamilton Health Sciences
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 905-521-2100
-
Hovedetterforsker:
- Uma H. Athale
-
London, Ontario, Canada, N6A 5W9
- Rekruttering
- Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 519-685-8306
-
Hovedetterforsker:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canada, K1H 8L1
- Rekruttering
- Children's Hospital of Eastern Ontario
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 613-737-7600
-
Hovedetterforsker:
- Donna L. Johnston
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- Hospital for Sick Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-post: ask.CRS@sickkids.ca
-
Hovedetterforsker:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Rekruttering
- The Montreal Children's Hospital of the MUHC
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-post: info@thechildren.com
-
Hovedetterforsker:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- Centre Hospitalier Universitaire Sainte-Justine
-
Hovedetterforsker:
- Monia Marzouki
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-post: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Rekruttering
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-post: crcinformation.chus@ssss.gouv.qc.ca
-
Hovedetterforsker:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Rekruttering
- Jim Pattison Children's Hospital
-
Hovedetterforsker:
- Kathleen Felton
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 306-655-3544
- E-post: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Rekruttering
- Children's Hospital of Alabama
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-post: oncologyresearch@peds.uab.edu
-
Hovedetterforsker:
- Elizabeth D. Alva
-
Mobile, Alabama, Forente stater, 36604
- Rekruttering
- USA Health Strada Patient Care Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Hovedetterforsker:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Forente stater, 85202
- Rekruttering
- Banner Children's at Desert
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Hovedetterforsker:
- Joseph C. Torkildson
-
Phoenix, Arizona, Forente stater, 85016
- Rekruttering
- Phoenix Childrens Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Hovedetterforsker:
- Alok K. Kothari
-
Tucson, Arizona, Forente stater, 85719
- Rekruttering
- Banner University Medical Center - Tucson
-
Ta kontakt med:
- Site Public Contact
- E-post: UACC-IIT@uacc.arizona.edu
-
Hovedetterforsker:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202-3591
- Rekruttering
- Arkansas Children's Hospital
-
Hovedetterforsker:
- Michael W. Bishop
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Downey, California, Forente stater, 90242
- Rekruttering
- Kaiser Permanente Downey Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Hovedetterforsker:
- Robert M. Cooper
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-post: becomingapatient@coh.org
-
Hovedetterforsker:
- Hung C. Tran
-
Loma Linda, California, Forente stater, 92354
- Rekruttering
- Loma Linda University Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Hovedetterforsker:
- Albert Kheradpour
-
Long Beach, California, Forente stater, 90806
- Rekruttering
- Miller Children's and Women's Hospital Long Beach
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Hovedetterforsker:
- Jacqueline N. Casillas
-
Los Angeles, California, Forente stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Hovedetterforsker:
- Araz Marachelian
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Hovedetterforsker:
- Fataneh (Fae) Majlessipour
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-post: Cancer.trial.info@cshs.org
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- Mattel Children's Hospital UCLA
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 310-825-6708
-
Hovedetterforsker:
- Satiro N. De Oliveira
-
Madera, California, Forente stater, 93636
- Rekruttering
- Valley Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-post: Research@valleychildrens.org
-
Hovedetterforsker:
- Ruetima Titapiwatanakun
-
Oakland, California, Forente stater, 94611
- Rekruttering
- Kaiser Permanente-Oakland
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-post: Kpoct@kp.org
-
Hovedetterforsker:
- Aarati V. Rao
-
Oakland, California, Forente stater, 94609
- Rekruttering
- UCSF Benioff Children's Hospital Oakland
-
Hovedetterforsker:
- Jennifer G. Michlitsch
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 510-428-3264
- E-post: PedOncRschOAK@ucsf.edu
-
Orange, California, Forente stater, 92868
- Rekruttering
- Children's Hospital of Orange County
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-post: oncresearch@choc.org
-
Hovedetterforsker:
- Elyssa M. Rubin
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital Stanford University
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-694-0012
- E-post: ccto-office@stanford.edu
-
Hovedetterforsker:
- Jay Michael S. Balagtas
-
Sacramento, California, Forente stater, 95817
- Rekruttering
- University of California Davis Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Hovedetterforsker:
- Marcio H. Malogolowkin
-
Sacramento, California, Forente stater, 95816
- Rekruttering
- Sutter Medical Center Sacramento
-
Ta kontakt med:
- Site Public Contact
- E-post: clinicalresearch@sutterhealth.org
-
Hovedetterforsker:
- Sandra Baril
-
San Diego, California, Forente stater, 92123
- Rekruttering
- Rady Children's Hospital - San Diego
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Hovedetterforsker:
- William D. Roberts
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- UCSF Medical Center-Mission Bay
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-post: cancertrials@ucsf.edu
-
Hovedetterforsker:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Children's Hospital Colorado
-
Hovedetterforsker:
- Navin R. Pinto
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-post: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Rekruttering
- Connecticut Children's Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Hovedetterforsker:
- Michael S. Isakoff
-
New Haven, Connecticut, Forente stater, 06520
- Rekruttering
- Yale University
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-post: canceranswers@yale.edu
-
Hovedetterforsker:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Rekruttering
- Alfred I duPont Hospital for Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Hovedetterforsker:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Children's National Medical Center
-
Hovedetterforsker:
- Jeffrey S. Dome
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-post: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33316
- Rekruttering
- Broward Health Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Hovedetterforsker:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Forente stater, 33908
- Rekruttering
- Golisano Children's Hospital of Southwest Florida
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-post: molly.arnstrom@leehealth.org
-
Hovedetterforsker:
- Emad K. Salman
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-post: cancer-center@ufl.edu
-
Hovedetterforsker:
- Brian Stover
-
Hollywood, Florida, Forente stater, 33021
- Rekruttering
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-post: OHR@mhs.net
-
Hovedetterforsker:
- Iftikhar Hanif
-
Jacksonville, Florida, Forente stater, 32207
- Rekruttering
- Nemours Children's Clinic-Jacksonville
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Hovedetterforsker:
- Sridhi Patel
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- Nicklaus Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Hovedetterforsker:
- Ziad A. Khatib
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hovedetterforsker:
- Meghan McCormick
-
Orlando, Florida, Forente stater, 32806
- Rekruttering
- Arnold Palmer Hospital for Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-post: Jennifer.spinelli@orlandohealth.com
-
Hovedetterforsker:
- Zhongbo Hu
-
Orlando, Florida, Forente stater, 32827
- Rekruttering
- Nemours Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-post: Allison.bruce@nemours.org
-
Hovedetterforsker:
- Sridhi Patel
-
Orlando, Florida, Forente stater, 32803
- Rekruttering
- AdventHealth Orlando
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-post: FH.Cancer.Research@flhosp.org
-
Hovedetterforsker:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Forente stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-post: Ashley.Repp@jhmi.edu
-
Hovedetterforsker:
- Jennifer B. Dean
-
West Palm Beach, Florida, Forente stater, 33407
- Rekruttering
- Saint Mary's Medical Center
-
Hovedetterforsker:
- Matthew D. Ramirez
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Hovedetterforsker:
- William T. Cash
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-post: Olivia.Floyd@choa.org
-
Savannah, Georgia, Forente stater, 31404
- Rekruttering
- Memorial Health University Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-post: Lorraine.OHara@hcahealthcare.com
-
Hovedetterforsker:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96826
- Rekruttering
- Kapiolani Medical Center for Women and Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Hovedetterforsker:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Lurie Children's Hospital-Chicago
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Hovedetterforsker:
- Elizabeth A. Sokol
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-post: cancerclinicaltrials@bsd.uchicago.edu
-
Hovedetterforsker:
- Ami V. Desai
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- University of Illinois
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hovedetterforsker:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Forente stater, 60453
- Rekruttering
- Advocate Children's Hospital-Oak Lawn
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 847-723-7570
-
Hovedetterforsker:
- Rebecca E. McFall
-
Park Ridge, Illinois, Forente stater, 60068
- Rekruttering
- Advocate Children's Hospital-Park Ridge
-
Ta kontakt med:
- Site Public Contact
- E-post: helpdesk@childrensoncologygroup.org
-
Hovedetterforsker:
- Rebecca E. McFall
-
Peoria, Illinois, Forente stater, 61637
- Rekruttering
- OSF Children's Hospital of Illinois
-
Hovedetterforsker:
- Prerna Kumar
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-post: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Hovedetterforsker:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Riley Hospital for Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Hovedetterforsker:
- Marissa Just
-
Indianapolis, Indiana, Forente stater, 46260
- Rekruttering
- Ascension Saint Vincent Indianapolis Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-post: research@stvincent.org
-
Hovedetterforsker:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Forente stater, 50309
- Rekruttering
- Blank Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-post: samantha.mallory@unitypoint.org
-
Hovedetterforsker:
- Samantha L. Mallory
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa/Holden Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Hovedetterforsker:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Forente stater, 67214
- Rekruttering
- Wesley Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 316-962-7802
- E-post: WesleyResearch@wesleymc.com
-
Hovedetterforsker:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- Rekruttering
- University of Kentucky/Markey Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hovedetterforsker:
- James T. Badgett
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Norton Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-post: CancerResource@nortonhealthcare.org
-
Hovedetterforsker:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70118
- Rekruttering
- Children's Hospital New Orleans
-
Hovedetterforsker:
- Maria C. Velez-Yanguas
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
-
Maine
-
Bangor, Maine, Forente stater, 04401
- Rekruttering
- Eastern Maine Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Hovedetterforsker:
- Daniel L. Callaway
-
Scarborough, Maine, Forente stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Hovedetterforsker:
- Sei-Gyung K. Sze
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-post: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Hovedetterforsker:
- Allen R. Chen
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-post: jhcccro@jhmi.edu
-
Baltimore, Maryland, Forente stater, 21215
- Rekruttering
- Sinai Hospital of Baltimore
-
Hovedetterforsker:
- Jason M. Fixler
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Baltimore, Maryland, Forente stater, 21201
- Rekruttering
- University of Maryland/Greenebaum Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Hovedetterforsker:
- Teresa A. York
-
Bethesda, Maryland, Forente stater, 20889-5600
- Rekruttering
- Walter Reed National Military Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Hovedetterforsker:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-726-5130
-
Hovedetterforsker:
- Lauren H. Boal
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Hovedetterforsker:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- C S Mott Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Hovedetterforsker:
- Rajen Mody
-
Detroit, Michigan, Forente stater, 48201
- Suspendert
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Forente stater, 49503
- Rekruttering
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-post: crcwm-regulatory@crcwm.org
-
Hovedetterforsker:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Forente stater, 49007
- Rekruttering
- Bronson Methodist Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-post: crcwm-regulatory@crcwm.org
-
Hovedetterforsker:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Forente stater, 48073
- Rekruttering
- Corewell Health Children's
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hovedetterforsker:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Rekruttering
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Hovedetterforsker:
- Michael K. Richards
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-post: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Forente stater, 55455
- Rekruttering
- University of Minnesota/Masonic Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Hovedetterforsker:
- Robin L. Williams
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic in Rochester
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hovedetterforsker:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216
- Rekruttering
- University of Mississippi Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Hovedetterforsker:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65212
- Rekruttering
- University of Missouri Children's Hospital
-
Hovedetterforsker:
- Barbara A. Gruner
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 573-882-1960
- E-post: snwq62@health.missouri.edu
-
Kansas City, Missouri, Forente stater, 64108
- Rekruttering
- Children's Mercy Hospitals and Clinics
-
Hovedetterforsker:
- Keith J. August
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-post: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Frederick S. Huang
-
St Louis, Missouri, Forente stater, 63141
- Rekruttering
- Mercy Hospital Saint Louis
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Hovedetterforsker:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Rekruttering
- Children's Hospital and Medical Center of Omaha
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Hovedetterforsker:
- Jill C. Beck
-
Omaha, Nebraska, Forente stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-post: unmcrsa@unmc.edu
-
Hovedetterforsker:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89135
- Rekruttering
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-post: research@sncrf.org
-
Hovedetterforsker:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Rekruttering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Hovedetterforsker:
- Angela Ricci
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-post: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Hovedetterforsker:
- Katharine Offer
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Morristown Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Hovedetterforsker:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Forente stater, 08901
- Rekruttering
- Saint Peter's University Hospital
-
Hovedetterforsker:
- Nibal A. Zaghloul
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-post: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Forente stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Hovedetterforsker:
- Nehal S. Parikh
-
Newark, New Jersey, Forente stater, 07112
- Rekruttering
- Newark Beth Israel Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-post: Christine.Kosmides@rwjbh.org
-
Hovedetterforsker:
- Teena Bhatla
-
Paterson, New Jersey, Forente stater, 07503
- Rekruttering
- Saint Joseph's Regional Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-post: HallL@sjhmc.org
-
Hovedetterforsker:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- Suspendert
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Forente stater, 12208
- Rekruttering
- Albany Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Hovedetterforsker:
- Lauren R. Weintraub
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-post: askroswell@roswellpark.org
-
Hovedetterforsker:
- Clare J. Twist
-
Mineola, New York, Forente stater, 11501
- Rekruttering
- NYU Langone Hospital - Long Island
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-post: cancertrials@nyulangone.org
-
Hovedetterforsker:
- Chana L. Glasser
-
New Hyde Park, New York, Forente stater, 11040
- Rekruttering
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Hovedetterforsker:
- Julie I. Krystal
-
New York, New York, Forente stater, 10032
- Rekruttering
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Hovedetterforsker:
- Nobuko Hijiya
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-post: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Forente stater, 10016
- Rekruttering
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Hovedetterforsker:
- Elizabeth A. Raetz
-
Ta kontakt med:
- Site Public Contact
- E-post: CancerTrials@nyulangone.org
-
Rochester, New York, Forente stater, 14642
- Rekruttering
- University of Rochester
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Hovedetterforsker:
- Rafi R. Kazi
-
Syracuse, New York, Forente stater, 13210
- Rekruttering
- State University of New York Upstate Medical University
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Hovedetterforsker:
- Melanie A. Comito
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Montefiore Medical Center - Moses Campus
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-post: eskwak@montefiore.org
-
Hovedetterforsker:
- Alice Lee
-
Valhalla, New York, Forente stater, 10595
- Rekruttering
- New York Medical College
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 914-594-3794
-
Hovedetterforsker:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28801
- Rekruttering
- Mission Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-post: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Hovedetterforsker:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- UNC Lineberger Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-post: cancerclinicaltrials@med.unc.edu
-
Hovedetterforsker:
- Thomas B. Alexander
-
Charlotte, North Carolina, Forente stater, 28203
- Rekruttering
- Carolinas Medical Center/Levine Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Hovedetterforsker:
- Joel A. Kaplan
-
Charlotte, North Carolina, Forente stater, 28204
- Rekruttering
- Novant Health Presbyterian Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-post: kashah@novanthealth.org
-
Hovedetterforsker:
- Holly Edington
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Medical Center
-
Hovedetterforsker:
- Jessica M. Sun
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Forente stater, 27834
- Rekruttering
- East Carolina University
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-post: eubankss@ecu.edu
-
Hovedetterforsker:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Hovedetterforsker:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58122
- Rekruttering
- Sanford Broadway Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-post: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Hovedetterforsker:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Forente stater, 44308
- Rekruttering
- Children's Hospital Medical Center of Akron
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Hovedetterforsker:
- Lauren R. Draper
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-post: cancer@cchmc.org
-
Hovedetterforsker:
- Katherine M. Somers
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic Foundation
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 866-223-8100
- E-post: TaussigResearch@ccf.org
-
Hovedetterforsker:
- Matteo M. Trucco
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- Rainbow Babies and Childrens Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Hovedetterforsker:
- Duncan S. Stearns
-
Columbus, Ohio, Forente stater, 43205
- Rekruttering
- Nationwide Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-post: Melinda.Triplet@nationwidechildrens.org
-
Hovedetterforsker:
- Mark A. Ranalli
-
Dayton, Ohio, Forente stater, 45404
- Rekruttering
- Dayton Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Hovedetterforsker:
- Jordan M. Wright
-
Toledo, Ohio, Forente stater, 43606
- Rekruttering
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-post: PCIOncResearch@promedica.org
-
Hovedetterforsker:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-post: ou-clinical-trials@ouhsc.edu
-
Hovedetterforsker:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Forente stater, 74136
- Rekruttering
- Saint Francis Children's Hospital
-
Hovedetterforsker:
- Jill A. Salo
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Forente stater, 97227
- Rekruttering
- Legacy Emanuel Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Hovedetterforsker:
- Jason M. Glover
-
Portland, Oregon, Forente stater, 97239
- Rekruttering
- Oregon Health and Science University
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-post: trials@ohsu.edu
-
Hovedetterforsker:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Rekruttering
- Lehigh Valley Hospital-Cedar Crest
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-post: Morgan_M.Horton@lvhn.org
-
Hovedetterforsker:
- Jacob A. Troutman
-
Danville, Pennsylvania, Forente stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Hovedetterforsker:
- Jagadeesh Ramdas
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-post: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Hovedetterforsker:
- Rochelle Bagatell
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-post: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Forente stater, 19134
- Rekruttering
- Saint Christopher's Hospital for Children
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Hovedetterforsker:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh of UPMC
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-post: jean.tersak@chp.edu
-
Hovedetterforsker:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02903
- Rekruttering
- Rhode Island Hospital
-
Hovedetterforsker:
- Bradley DeNardo
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-post: hcc-clinical-trials@musc.edu
-
Hovedetterforsker:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Forente stater, 29203
- Rekruttering
- Prisma Health Richland Hospital
-
Hovedetterforsker:
- Stuart L. Cramer
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-post: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Forente stater, 29605
- Rekruttering
- BI-LO Charities Children's Cancer Center
-
Hovedetterforsker:
- Aniket Saha
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-post: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57117-5134
- Rekruttering
- Sanford USD Medical Center - Sioux Falls
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-post: OncologyClinicalTrialsSF@SanfordHealth.org
-
Hovedetterforsker:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37916
- Rekruttering
- East Tennessee Childrens Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Hovedetterforsker:
- Susan E. Spiller
-
Memphis, Tennessee, Forente stater, 38105
- Rekruttering
- Saint Jude Children's Research Hospital
-
Hovedetterforsker:
- Sara M. Federico
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-226-4343
- E-post: referralinfo@stjude.org
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University/Ingram Cancer Center
-
Hovedetterforsker:
- Daniel J. Benedetti
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- The Children's Hospital at TriStar Centennial
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Hovedetterforsker:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Forente stater, 78723
- Rekruttering
- Dell Children's Medical Center of Central Texas
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-post: TXAUS-DL-SFCHemonc.research@ascension.org
-
Hovedetterforsker:
- Shannon M. Cohn
-
Corpus Christi, Texas, Forente stater, 78411
- Rekruttering
- Driscoll Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-post: Crystal.DeLosSantos@dchstx.org
-
Hovedetterforsker:
- Nkechi I. Mba
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Hovedetterforsker:
- Tanya C. Watt
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Forente stater, 75230
- Rekruttering
- Medical City Dallas Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Hovedetterforsker:
- Maurizio L. Ghisoli
-
El Paso, Texas, Forente stater, 79905
- Rekruttering
- El Paso Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-post: ranjan.bista@ttuhsc.edu
-
Hovedetterforsker:
- Benjamin Carcamo
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- Cook Children's Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-post: CookChildrensResearch@cookchildrens.org
-
Hovedetterforsker:
- Chelsee Greer
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-post: burton@bcm.edu
-
Hovedetterforsker:
- Jennifer H. Foster
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- UT MD Anderson Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-post: askmdanderson@mdanderson.org
-
Hovedetterforsker:
- Najat C. Daw
-
Lubbock, Texas, Forente stater, 79410
- Rekruttering
- Covenant Children's Hospital
-
Hovedetterforsker:
- Kishor M. Bhende
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-post: mbisbee@providence.org
-
Lubbock, Texas, Forente stater, 79415
- Rekruttering
- UMC Cancer Center / UMC Health System
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Hovedetterforsker:
- Erin K. Barr
-
San Antonio, Texas, Forente stater, 78207
- Rekruttering
- Children's Hospital of San Antonio
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-post: bridget.medina@christushealth.org
-
Hovedetterforsker:
- Julie Voeller
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- University of Texas Health Science Center at San Antonio
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-post: phoresearchoffice@uthscsa.edu
-
Hovedetterforsker:
- Aaron J. Sugalski
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Methodist Children's Hospital of South Texas
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-post: Vinod.GidvaniDiaz@hcahealthcare.com
-
Hovedetterforsker:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Rekruttering
- Primary Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Hovedetterforsker:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05405
- Rekruttering
- University of Vermont and State Agricultural College
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-post: rpo@uvm.edu
-
Hovedetterforsker:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- Rekruttering
- University of Virginia Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-post: uvacancertrials@hscmail.mcc.virginia.edu
-
Hovedetterforsker:
- Brian C. Belyea
-
Portsmouth, Virginia, Forente stater, 23708-2197
- Rekruttering
- Naval Medical Center - Portsmouth
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 757-953-5939
-
Hovedetterforsker:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Seattle Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Hovedetterforsker:
- Sarah E. Leary
-
Spokane, Washington, Forente stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-post: HopeBeginsHere@providence.org
-
Hovedetterforsker:
- Judy L. Felgenhauer
-
Tacoma, Washington, Forente stater, 98405
- Rekruttering
- Mary Bridge Children's Hospital and Health Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-post: research@multicare.org
-
Hovedetterforsker:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Forente stater, 25701
- Rekruttering
- Edwards Comprehensive Cancer Center
-
Hovedetterforsker:
- Mark A. Ranalli
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-post: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Forente stater, 26506
- Rekruttering
- West Virginia University Healthcare
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-post: cancertrialsinfo@hsc.wvu.edu
-
Hovedetterforsker:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Forente stater, 54301
- Suspendert
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Forente stater, 53792
- Rekruttering
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-post: clinicaltrials@cancer.wisc.edu
-
Hovedetterforsker:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Forente stater, 54449
- Rekruttering
- Marshfield Medical Center-Marshfield
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-post: oncology.clinical.trials@marshfieldresearch.org
-
Hovedetterforsker:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Forente stater, 53226
- Rekruttering
- Children's Hospital of Wisconsin
-
Hovedetterforsker:
- Angela Steineck
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-post: MACCCTO@mcw.edu
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1145
- Rekruttering
- Starship Children's Hospital
-
Hovedetterforsker:
- Andrew C. Wood
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 0800 728 436
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekruttering
- University Pediatric Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Hovedetterforsker:
- Maria E. Echevarria
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm A (SOC treatment)
See detailed description |
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo bone marrow biopsy
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo MUGA
Andre navn:
Undergo bone marrow aspiration Given IV
Andre navn:
Undergo CT scan
Andre navn:
Given IV
Andre navn:
Undergo radiation therapy
Andre navn:
Undergo blood and urine sample collection
Andre navn:
Ancillary studies Given IV
Andre navn:
Given IV Given IV
Andre navn:
Given IV
Andre navn:
Undergo FDG PET
Andre navn:
Undergo stem cell infusion
Andre navn:
Given PO
Andre navn:
Undergo apheresis
Andre navn:
Undergo I-MIBG scan
Andre navn:
Given PO or via NG or G tube
Andre navn:
Undergo tumor resection surgery |
|
Eksperimentell: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo bone marrow biopsy
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo MUGA
Andre navn:
Undergo bone marrow aspiration Given IV
Andre navn:
Undergo CT scan
Andre navn:
Given IV
Andre navn:
Undergo radiation therapy
Andre navn:
Undergo blood and urine sample collection
Andre navn:
Ancillary studies Given IV
Andre navn:
Given IV Given IV
Andre navn:
Given IV
Andre navn:
Undergo FDG PET
Andre navn:
Undergo stem cell infusion
Andre navn:
Given PO
Andre navn:
Undergo apheresis
Andre navn:
Undergo I-MIBG scan
Andre navn:
Given PO or via NG or G tube
Andre navn:
Undergo tumor resection surgery |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival (EFS)
Tidsramme: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
End of Induction (EOI) response rate
Tidsramme: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Tidsramme: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Tidsramme: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Tidsramme: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Association between tumor and host factors and outcomes
Tidsramme: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Tidsramme: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Tidsramme: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Tidsramme: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Tidsramme: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Tidsramme: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Tidsramme: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Tidsramme: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Tidsramme: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Tidsramme: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Tidsramme: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Tidsramme: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Tidsramme: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Tidsramme: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Sara M Federico, Children's Oncology Group
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Neuroektodermale svulster, primitive, perifere
- Neuroektodermale svulster, primitive
- Nevroblastom
- Ganglioneuroblastom
- Organisasjon og administrasjon
- Health Services Administration
- Aminosyrer, peptider og proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Undersøkelsesteknikker
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Azoler
- Cytologiske teknikker
- Cytodiagnose
- Retinoider
- Karotenoider
- Polyener
- Alkenes
- Hydrokarboner, acyklisk
- Hydrokarboner
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Pigmenter, biologisk
- Biologiske faktorer
- Karbohydrater
- Fysiske fenomener
- Camptothecin
- Alkaloider
- Podofyllotoksin
- Tetrahydronaftalener
- Naftalener
- Polysykliske aromatiske hydrokarboner
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Glukosider
- Glykosider
- Dacarbazine
- Triazener
- Imidazoles
- Transplantasjon
- Indoler
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Aminosyrer
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Hydrokarboner, halogenert
- Fosforamider
- Organofosforforbindelser
- Metaller, tunge
- Vinca -alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indolisiner
- Antracykliner
- Naphthacenes
- Aminoglykosider
- Platinumforbindelser
- Daunorubicin
- Overgangselementer
- Celletransplantasjon
- Celle- og vevsbasert terapi
- Biologisk terapi
- Cytapheresis
- Fjerning av blodkomponent
- Prosedyrer for leukocyttreduksjon
- Celles separasjon
- Fenylalanin
- Aminosyrer, aromatiske
- Aminosyrer, syklisk
- Sykehusadministrasjon
- Health Facility Administration
- Trietylenefosforamid
- Aziridiner
- Aziriner
- Urologiske kirurgiske inngrep
- Urogenitale kirurgiske inngrep
- Temozolomid
- Irinotekan
- Cyklofosfamid
- Melphalan
- Etoposid
- Karboplatin
- Doxorubicin
- Vincristine
- Cisplatin
- Isotretinoin
- Thiotepa
- Topotekan
- 1,2-diaminocykloheksanplatina II sitrat
- Strålebehandling
- Stråling
- Biopsi
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Platinum
- dinutuximab
- Stamcelletransplantasjon
- Hematopoietisk stamcelletransplantasjon
- Leukapheresis
- Avdeling for nukleærmedisin, sykehus
- Transuretral reseksjon av blære
Andre studie-ID-numre
- NCI-2023-08530
- U10CA180886 (U.S. NIH-stipend/kontrakt)
- NCI-2023-08530 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Annen identifikator: CTEP)
- ANBL2131 (Annen identifikator: Children's Oncology Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .